Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen’s Phosphate Binder Loss May Be Genzyme’s Gain

This article was originally published in The Pink Sheet Daily

Executive Summary

Once expected to plunder Renagel market share, AMG 223 suddenly gets left on the shelf.

You may also be interested in...

Sanofi Licenses Possible Renagel/Renvela Successor From Ardelyx

The French pharma paid an undisclosed amount for rights to a preclinical phosphate transport program, one of several non-absorbable drugs that act locally within the gut. The deal comes as market-leading Renagel and Renvela face imminent generic competition.

Biotech IPO Candidates Ramp Up To Get Out Before The Holidays

After a bit of a lull since September, there are seven biotechnology IPOs slated to get out in the next few weeks. But they are entering a tougher market than earlier in 2013, and some may not be quite the same quality.

Relypsa Adds Venture Funds In Another Effort To Reach Phase III

Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts